AI assistant
Sending…
Spero Therapeutics, Inc. — Director's Dealing 2024
May 30, 2024
34087_dirs_2024-05-30_d272d4bd-8a66-4a08-968d-3d910a10c407.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Spero Therapeutics, Inc. (SPRO)
CIK: 0001701108
Period of Report: 2024-05-29
Reporting Person: Jackson Scott Thomas (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-29 | Common Stock | A | 20000 | $0.00 | Acquired | 55000 | Direct |
Footnotes
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on May 29, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
More from Spero Therapeutics, Inc.
Regulatory Filings
2026
May 13
Annual Report
2026
Apr 27
Proxy Solicitation & Information Statement
2026
Apr 27
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 10
Director's Dealing
2026
Feb 5
Director's Dealing
2026
Feb 4
Regulatory Filings
2026
Jan 30
Regulatory Filings
2025
Dec 19
Regulatory Filings
2025
Nov 13